A decrease in CPT1A gene expression level was observed for all three active treatments while SLC25A20 showed statistically significant reduction in gene expression levels under VitD3-containing (VitD3 and VitD3 + BPH) treatments. Here, CPT1A is linked to benign prostatic hyperplasia.